Welcome!

News Feed Item

Fatty Liver Disease Global Clinical Trials Review, H2, 2014

LONDON, Sept. 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Fatty Liver Disease Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/617103/Fatty-Liver-Disease-Global-Clinical-Trials-Review-H2-2014.html

Fatty Liver Disease Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Fatty Liver Disease Global Clinical Trials Review, H2, 2014" provides data on the Fatty Liver Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Fatty Liver Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Fatty Liver Disease. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Fatty Liver Disease 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Fatty Liver Disease 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Fatty Liver Disease Therapeutics Clinical Trials 30
Prominent Drugs 32
Latest Clinical Trials News on Fatty Liver Disease 33
Jul 30, 2014: Galectin Therapeutics Issues Statement on GR-MD-02 Development Program 33
Jul 25, 2014: Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis 34
Clinical Trial Profiles 35
Clinical Trial Overview of Top Companies 35
Merck & Co., Inc. 35
Clinical Trial Overview of Merck & Co., Inc. 35
Galmed International Ltd. 36
Clinical Trial Overview of Galmed International Ltd. 36
F. Hoffmann-La Roche Ltd. 37
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 37
PharmaKing Co., Ltd. 38
Clinical Trial Overview of PharmaKing Co., Ltd. 38
Abbott Laboratories 39
Clinical Trial Overview of Abbott Laboratories 39
TCM Biotech International Corp 40
Clinical Trial Overview of TCM Biotech International Corp 40
Sanofi 41
Clinical Trial Overview of Sanofi 41
Phenex Pharmaceuticals AG 42
Clinical Trial Overview of Phenex Pharmaceuticals AG 42
GW Pharmaceuticals plc 43
Clinical Trial Overview of GW Pharmaceuticals plc 43
Genextra S.p.a. 44
Clinical Trial Overview of Genextra S.p.a. 44
Clinical Trial Overview of Top Institutes / Government 45
The National Institute of Diabetes and Digestive and Kidney Diseases 45
Clinical Trial Overview of The National Institute of Diabetes and Digestive and Kidney Diseases 45
Tabriz University of Medical Sciences 46
Clinical Trial Overview of Tabriz University of Medical Sciences 46
Third Military Medical University 47
Clinical Trial Overview of Third Military Medical University 47
University of Michigan 48
Clinical Trial Overview of University of Michigan 48
Tehran University of Medical Sciences 49
Clinical Trial Overview of Tehran University of Medical Sciences 49
Washington University School of Medicine 50
Clinical Trial Overview of Washington University School of Medicine 50
University of California, San Diego 51
Clinical Trial Overview of University of California, San Diego 51
FUDAN University 52
Clinical Trial Overview of FUDAN University 52
Ahvaz Jundishapur University of Medical Sciences 53
Clinical Trial Overview of Ahvaz Jundishapur University of Medical Sciences 53
Bambino Gesu Hospital and Research Institute 54
Clinical Trial Overview of Bambino Gesu Hospital and Research Institute 54
Five Key Clinical Profiles 55
Appendix 82
Abbreviations 82
Definitions 82
Research Methodology 83
Secondary Research 84
About GlobalData 84
Contact Us 84
Disclaimer 84
Source 85

List of Tables
Fatty Liver Disease Therapeutics, Global, Clinical Trials by Region, 2014* 7
Fatty Liver Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Fatty Liver Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Fatty Liver Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Fatty Liver Disease Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Fatty Liver Disease Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Fatty Liver Disease Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Fatty Liver Disease Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials, G7 Countries (%), 2014* 15
Fatty Liver Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Fatty Liver Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials, E7 Countries (%), 2014* 18
Fatty Liver Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Fatty Liver Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Fatty Liver Disease Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Fatty Liver Disease Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Fatty Liver Disease Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Fatty Liver Disease Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Fatty Liver Disease Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Fatty Liver Disease Therapeutics, Global, Terminated Clinical Trials, 2014* 26
Fatty Liver Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Fatty Liver Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 28
Fatty Liver Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Fatty Liver Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 31
Fatty Liver Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 35
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Galmed International Ltd., 2014* 36
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 37
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by PharmaKing Co., Ltd., 2014* 38
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Abbott Laboratories, 2014* 39
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by TCM Biotech International Corp, 2014* 40
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 41
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Phenex Pharmaceuticals AG, 2014* 42
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by GW Pharmaceuticals plc, 2014* 43
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Genextra S.p.a., 2014* 44
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Diabetes and Digestive and Kidney Diseases, 2014* 45
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Tabriz University of Medical Sciences, 2014* 46
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Third Military Medical University, 2014* 47
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Michigan, 2014* 48
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2014* 49
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2014* 50
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Diego, 2014* 51
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by FUDAN University, 2014* 52
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Ahvaz Jundishapur University of Medical Sciences, 2014* 53
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Bambino Gesu Hospital and Research Institute, 2014* 54

List of Figures
Fatty Liver Disease Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Fatty Liver Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Fatty Liver Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Fatty Liver Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Fatty Liver Disease Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Fatty Liver Disease Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Fatty Liver Disease Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Fatty Liver Disease Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014* 14
Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials, G7 Countries (%), 2014* 15
Fatty Liver Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Fatty Liver Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials, E7 Countries (%), 2014* 18
Fatty Liver Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Fatty Liver Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Fatty Liver Disease Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Fatty Liver Disease Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Fatty Liver Disease Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Fatty Liver Disease Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Fatty Liver Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Fatty Liver Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 28
Fatty Liver Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Fatty Liver Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Fatty Liver Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
GlobalData Methodology 83

Read the full report:
Fatty Liver Disease Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/617103/Fatty-Liver-Disease-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"Storpool does only block-level storage so we do one thing extremely well. The growth in data is what drives the move to software-defined technologies in general and software-defined storage," explained Boyan Ivanov, CEO and co-founder at StorPool, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
Sometimes I write a blog just to formulate and organize a point of view, and I think it’s time that I pull together the bounty of excellent information about Machine Learning. This is a topic with which business leaders must become comfortable, especially tomorrow’s business leaders (tip for my next semester University of San Francisco business students!). Machine learning is a key capability that will help organizations drive optimization and monetization opportunities, and there have been some...
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
The question before companies today is not whether to become intelligent, it’s a question of how and how fast. The key is to adopt and deploy an intelligent application strategy while simultaneously preparing to scale that intelligence. In her session at 21st Cloud Expo, Sangeeta Chakraborty, Chief Customer Officer at Ayasdi, provided a tactical framework to become a truly intelligent enterprise, including how to identify the right applications for AI, how to build a Center of Excellence to oper...
While some developers care passionately about how data centers and clouds are architected, for most, it is only the end result that matters. To the majority of companies, technology exists to solve a business problem, and only delivers value when it is solving that problem. 2017 brings the mainstream adoption of containers for production workloads. In his session at 21st Cloud Expo, Ben McCormack, VP of Operations at Evernote, discussed how data centers of the future will be managed, how the p...
ChatOps is an emerging topic that has led to the wide availability of integrations between group chat and various other tools/platforms. Currently, HipChat is an extremely powerful collaboration platform due to the various ChatOps integrations that are available. However, DevOps automation can involve orchestration and complex workflows. In his session at @DevOpsSummit at 20th Cloud Expo, Himanshu Chhetri, CTO at Addteq, will cover practical examples and use cases such as self-provisioning infra...
As DevOps methodologies expand their reach across the enterprise, organizations face the daunting challenge of adapting related cloud strategies to ensure optimal alignment, from managing complexity to ensuring proper governance. How can culture, automation, legacy apps and even budget be reexamined to enable this ongoing shift within the modern software factory? In her Day 2 Keynote at @DevOpsSummit at 21st Cloud Expo, Aruna Ravichandran, VP, DevOps Solutions Marketing, CA Technologies, was jo...
As Marc Andreessen says software is eating the world. Everything is rapidly moving toward being software-defined – from our phones and cars through our washing machines to the datacenter. However, there are larger challenges when implementing software defined on a larger scale - when building software defined infrastructure. In his session at 16th Cloud Expo, Boyan Ivanov, CEO of StorPool, provided some practical insights on what, how and why when implementing "software-defined" in the datacent...
Blockchain. A day doesn’t seem to go by without seeing articles and discussions about the technology. According to PwC executive Seamus Cushley, approximately $1.4B has been invested in blockchain just last year. In Gartner’s recent hype cycle for emerging technologies, blockchain is approaching the peak. It is considered by Gartner as one of the ‘Key platform-enabling technologies to track.’ While there is a lot of ‘hype vs reality’ discussions going on, there is no arguing that blockchain is b...
Blockchain is a shared, secure record of exchange that establishes trust, accountability and transparency across business networks. Supported by the Linux Foundation's open source, open-standards based Hyperledger Project, Blockchain has the potential to improve regulatory compliance, reduce cost as well as advance trade. Are you curious about how Blockchain is built for business? In her session at 21st Cloud Expo, René Bostic, Technical VP of the IBM Cloud Unit in North America, discussed the b...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
Is advanced scheduling in Kubernetes achievable?Yes, however, how do you properly accommodate every real-life scenario that a Kubernetes user might encounter? How do you leverage advanced scheduling techniques to shape and describe each scenario in easy-to-use rules and configurations? In his session at @DevOpsSummit at 21st Cloud Expo, Oleg Chunikhin, CTO at Kublr, answered these questions and demonstrated techniques for implementing advanced scheduling. For example, using spot instances and co...
The cloud era has reached the stage where it is no longer a question of whether a company should migrate, but when. Enterprises have embraced the outsourcing of where their various applications are stored and who manages them, saving significant investment along the way. Plus, the cloud has become a defining competitive edge. Companies that fail to successfully adapt risk failure. The media, of course, continues to extol the virtues of the cloud, including how easy it is to get there. Migrating...
The use of containers by developers -- and now increasingly IT operators -- has grown from infatuation to deep and abiding love. But as with any long-term affair, the honeymoon soon leads to needing to live well together ... and maybe even getting some relationship help along the way. And so it goes with container orchestration and automation solutions, which are rapidly emerging as the means to maintain the bliss between rapid container adoption and broad container use among multiple cloud host...
Imagine if you will, a retail floor so densely packed with sensors that they can pick up the movements of insects scurrying across a store aisle. Or a component of a piece of factory equipment so well-instrumented that its digital twin provides resolution down to the micrometer.